298 patents
Utility
Bifunctional Degraders of Hematopoietic Progenitor Kinase and Therapeutic Uses Thereof
18 Jan 24
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
Filed: 9 Nov 22
Utility
Methods for Treatment of Viral Infections
11 Jan 24
The present disclosure relates to methods for treating viral infections in a patient that is not pregnant.
Roy Maxim Bannister, John P. Bilello, Jared D. Pitts
Filed: 5 Jun 23
Utility
Tetracyclic Compounds and Uses Thereof
11 Jan 24
The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions.
Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
Filed: 12 May 23
Utility
Lpa Receptor Antagonists and Uses Thereof
4 Jan 24
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1.
Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
Filed: 24 May 23
Utility
Engineered CD200R Antibodies and Uses Thereof
28 Dec 23
In some aspects, provided herein are antibodies or antigen-binding fragments that bind to CD200R, a glycoprotein receptor present on cell surfaces.
Simon John DAVIS, Richard John CORNALL, Christopher Douglas PALUCH, Lynne Anne MURRAY, Nathan Jacob ROBERTSON, Eleanor Marysia SCOTT, Daniela M. TOMAZELA
Filed: 5 Apr 23
Utility
GLP-1R Modulating Compounds
7 Dec 23
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof.
Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
Filed: 10 May 23
Utility
Antiviral Compounds and Methods of Making and Using the Same
30 Nov 23
Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L. Mackman, Devan Naduthambi, Dustin S. Siegel
Filed: 1 Mar 23
Utility
Ikaros Zinc Finger Family Degraders and Uses Thereof
23 Nov 23
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos).
Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
Filed: 15 Mar 23
Utility
Kras G12D Modulating Compounds
23 Nov 23
Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
Chaodi Dai, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Maoqun Tian, Vickie H. Tsui, William J. Watkins, Adam D. Zajdlik, Jennifer R. Zhang
Filed: 20 Apr 23
Utility
Antiviral Pyrazolopiridinone Compounds
16 Nov 23
Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
Filed: 6 Feb 23
Utility
Combination Therapy for Treating Colorectal Cancer
16 Nov 23
Provided are methods of treating colorectal cancer in a subject comprising co-administering to the subject an effective amount of: (a) an agent that inhibits binding between CD47 and SIRPα (e.g., magrolimab); and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors (e.g., bevacizumab), optionally further including a chemotherapy regimen (e.g., FOLFIRI).
Mark P. Chao, William J. Grossman, Fatema A. Legrand
Filed: 3 Apr 23
Utility
Solid Forms of a Toll-like Receptor Modulator
16 Nov 23
The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
Sylvie M. Asselin, Pavel R. Badalov, Henry G. Morrison, Christopher S. Regens, Tiago Vieira
Filed: 13 Dec 22
Utility
PARP7 Inhibitors
16 Nov 23
Jayaraman Chandrasekhar, Jonah J. Chang, Kevin S. Currie, Stephen D. Holmbo, Jesse M. Jacobsen, David L. Kukla, Seung H. Lee, Yasamin Moazami, Leena B. Patel, Thomas J. Paul, Stephane Perreault, Patrick J. Salvo, Jennifer A. Treiberg, Heath A. Weaver
Filed: 26 Jan 23
Utility
Thienopyrrole Compounds
16 Nov 23
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions.
Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
Filed: 8 Mar 23
Utility
Combination Therapy for Treating TROP-2 Expressing Cancers
9 Nov 23
Provided are methods of treating, mitigating, or preventing or delaying the growth, proliferation, recurrence or metastasis of, a Trop-2 expressing cancer in a subject by administering an effective amount of: (a) an agent that inhibits binding between CD47 and SIRPα (e.g., magrolimab); and (b) an anti-Trop-2 antibody drug conjugate (ADC) (e.g., sacituzumab govitecan) to the subject.
Mark P. Chao, William J. Grossman, Inderjit D. Lal, Fatema A. Legrand, Nathalie Scholler, Jamie G. Bates, Hikmat H. Assi, Chih-Chien Chou
Filed: 21 Mar 23
Utility
Salts and Polymorphs of Certain MCL-1 Inhibitors
9 Nov 23
The present disclosure relates salts and the crystalline forms of certain 3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof.
John Enquist, Michael A. Ischay, Olga V. Lapina, David W. Lin, Christopher S. Regens, David A. Siler, Eric A. Standley, Sarah E. Wortman
Filed: 3 May 23
Utility
Methods for Treating Sars COV-2 Infections
2 Nov 23
Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
Filed: 5 Apr 23
Utility
MCL1 Inhibitors
2 Nov 23
Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
Filed: 9 Mar 23
Utility
Crystalline Forms of (S)-2-ETHYLBUTYL 2-(((S)-(((2R,3S,4R,5R)-5- (4-AMINOPYRROLO[2,1-F] [1,2,4]TRIAZIN-7-YL)-5-CYANO-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHOXY) (Phenoxy) Phosphoryl)amino)propanoate
2 Nov 23
The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections.
Katrien Brak, Ernest A. Carra, Lars V. Heumann, Nate Larson
Filed: 20 Jan 23
Utility
Bridged Tricyclic Carbamoylpyridone Compounds and Uses Thereof
26 Oct 23
Hang Chu, Ana Z. Gonzalez Buenrostro, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, Gregg M. Schwarzwalder, Devleena M. Shivakumar, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang
Filed: 14 Jun 23